Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099259 | 0.89 | SIGMAR1 (0.80) | SIGMAR1DRD2TMEM97ACHE | |
| SCHEMBL18099333 | 0.89 | SIGMAR1 (0.80) | SIGMAR1DRD2TMEM97ACHE | |
| SCHEMBL18099323 | 0.85 | SIGMAR1 (0.74) | SIGMAR1DRD2TMEM97ACHE | |
| SCHEMBL18100722 | 0.76 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHE | |
| SCHEMBL16408564 | 0.76 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHE | |
| SCHEMBL16402314 | 0.76 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHE | |
| SCHEMBL18099347 | 0.76 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHE | |
| SCHEMBL18099297 | 0.76 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHE | |
| SCHEMBL21871140 | 0.76 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHE | |
| SCHEMBL18099210 | 0.75 | SIGMAR1 (0.59) | SIGMAR1DRD2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885DRD2 220/4885TMEM97 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.